Vincerx Pharma, Inc.
OTC: VINC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Raquel E. Izumi
- Employees
- 12
- Headquarters
- Palo Alto, United States
- IPO year
- 2020
- Market cap
- $66.5K
- Website
- https://vincerx.com
Loading VINC…
Loading profile data…Frequently asked questions about VINC
What does Vincerx Pharma, Inc. (VINC) do?
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for in...
Where does VINC trade?
Vincerx Pharma, Inc. (VINC) trades on the Other OTC.
What sector is VINC in?
Vincerx Pharma, Inc. (VINC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vincerx Pharma, Inc.?
Raquel E. Izumi is the chief executive officer of Vincerx Pharma, Inc. (VINC).
Where is Vincerx Pharma, Inc. headquartered?
Vincerx Pharma, Inc. is headquartered in United States.
Does VINC pay a dividend?
Vincerx Pharma, Inc. (VINC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VINC go public?
Vincerx Pharma, Inc. (VINC) completed its initial public offering in 2020.